90531-99-0

Upstream product

• 1203655-89-3 sodium 5-bromo-2-methoxybenzenesulfinate 
• 74-88-4 methyl iodide 
• 23095-05-8 5-bromo-2-methoxybenzenesulfonyl chloride 
• 77-78-1 dimethyl sulfate 
• 3185-99-7 Methyl p-tolyl sulfone 

Downstream Products

• 918328-09-3 2-(4-methoxy-3-(methylsulfonyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1203652-17-8 4-((6-(4-methoxy-3-(methylsulfonyl)phenyl)-4-(2,2,2-trifluoroethylamino)pyrido[3,2-d]pyrimidin-2-ylamino)methyl)benzenesulfonamide 
• 1203653-35-3 (R)-N₂-(1-(4-(1H-1,2,4-triazol-1-yl)phenyl)ethyl)-6-(4-methoxy-3-(methylsulfonyl)phenyl)-N₄-(2,2,2-trifluoroethyl)pyrido[3,2-d]pyrimidine-2,4-diamine 
• 1421747-02-5 C₁₄H₁₅NO₃S 
• 1020735-54-9 4-{3-[4-methoxy-3-(methylsulfonyl)phenoxy]phenyl}-3-methyl-8-(trifluoromethyl)quinoline 
• 346729-52-0 1-(3-Methanesulfonyl-4-methoxy-phenyl)-piperazine 

Relevant academic research and scientific papers

PI4KIIIBETA INHIBITORS

The invention relates to compounds of formula (I) which are inhibitors of kinase activity, pharmaceutical formulations containing the compounds and their uses in treating and preventing viral infections and disorders caused or exacerbated by the viral inf

ORGANOMETALLIC COMPLEX AND ORGANIC LIGHT EMITTING ELEMENT INCLUDING THE SAME

The present invention provides an organometallic complex useful as a guest material of a blue phosphorescent light emitting element. In addition, the present invention also provides an organic light emitting element having a high luminescent efficiency. A

HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES

The invention relates to compounds of Formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.

Optimization of pharmacokinetics through manipulation of physicochemical properties in a series of HCV inhibitors

A novel series of HCV replication inhibitors based on a pyrido[3,2-d]pyrimidine core were optimized for pharmacokinetics (PK) in rats. Several associations between physicochemical properties and PK were identified and exploited to guide the design of comp

2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS

Pyrido(3,2-d)pyrimidine derivatives represented by the structural formuia (Ia): wherein, R1, R2 and R3 are defined herein, pharmaceutical acceptable addition salts, stereochemical isomeric forms, N-oxides, solvates and pro